Most protocols maintain this for the first four weeks before moving to the titration phase
Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: A randomised, double-blind, placebo-controlled trial
Metabolic Support: Improves insulin sensitivity and energy balance
Tennis champion Serena Williams has publicly discussed her use of GLP-1 medications and has partnered with a health company that connects consumers with telehealth weight-loss services
Clinical studies, such as the STEP trials, have shown that adults using semaglutide GLP-1 at the recommended dose (2.4 mg weekly) can lose an average of about 15% of their initial body weight over 68 weeks when combined with healthy lifestyle changes
Introduced around the 2000s, these drugs have opened new avenues in weight management strategies, heralding a paradigm shift in obesity treatment